Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 29, Pages 11818-11823Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1205995109
Keywords
Kaposi sarcoma-associated herpesvirus; metabolism
Categories
Funding
- National Institutes of Health [DK056350]
- National Cancer Institute
- University of North Carolina University Cancer Research Fund
- [T32-AI007419]
- [T32-CA071341]
- [T32-CA09156]
- [T32AI007151]
- [CA096500]
- [DE018304]
- [CA163217]
- [AA017376]
- [ES019472]
- [P30DK034987]
- [CA123350]
Ask authors/readers for more resources
The metabolic differences between B-NHL and primary human B cells are poorly understood. Among human B-cell non-Hodgkin lymphomas (B-NHL), primary effusion lymphoma (PEL) is a unique subset that is linked to infection with Kaposi's sarcoma-associated herpesvirus (KSHV). We report that the metabolic profiles of primary B cells are significantly different from that of PEL. Compared with primary B cells, both aerobic glycolysis and fatty acid synthesis (FAS) are up-regulated in PEL and other types of nonviral B-NHL. We found that aerobic glycolysis and FAS occur in a PI3K-dependent manner and appear to be interdependent. PEL overexpress the fatty acid synthesizing enzyme, FASN, and both PEL and other B-NHL were much more sensitive to the FAS inhibitor, C75, than primary B cells. Our findings suggest that FASN may be a unique candidate for molecular targeted therapy against PEL and other B-NHL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available